Claims
- 1. A method of ameliorating erectile dysfunction in a male patient which comprises administering to said patient apomorphine or a pharmaceutically acceptable acid addition salt thereof prior to sexual activity, in an amount sufficient to induce an erection adequate for vaginal penetration but less than an amount that induces nausea and to maintain a plasma concentration of apomorphine at a level of no more than about 5.5 ng/ml.
- 2. The method in accordance with claim 1 wherein the plasma concentration of apomorphine is maintained at a level of about 0.3 to about 4 ng/ml.
- 3. The method in accordance with claim 1 wherein the plasma concentration of apomorphine is maintained at a level of about 1 to about 2 ng/ml.
- 4. The method in accordance with claim 1 wherein the amount of apomorphine administered is in the range of about 2.5 milligrams to about 10 milligrams.
- 5. The method in accordance with claim 1 wherein the amount of apomorphine administered is in the range of about 25 to about 75 micrograms per kilogram of body weight.
- 6. The method in accordance with claim 1 wherein apomorphine is administered as the hydrochloride salt.
- 7. The method in accordance with claim 1 wherein the apomorphine is administered together with an anti-emetic agent.
- 8. The method in accordance with claim 7 wherein the antiemetic agent is domperidone.
- 9. A method of inducing an erection by stimulating dopamine receptors in the mid-brain region of a patient to cause an erection without inducing nausea which comprises administering to the patient apomorphine in a dose containing about 25 to about 60 micrograms of apomorphine per kilogram of body weight and at a rate so as to maintain a patient's plasma concentration of apomorphine at a value of no more than about 5.5 nanograms per milliliter during sexual activity.
- 10. The method in accordance with claim 9 wherein the patient's plasma concentration of apomorphine is maintained in the range of about 0.3 to about 4 nanograms per milliliter during sexual activity.
- 11. The method in accordance with claim 9 wherein the patient's plasma concentration of apomorphine is maintained in the range of about 1 to about 2 nanograms per milliliter during sexual activity.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of co-pending application U.S. Ser. No. 10/044,588, filed on Oct. 23, 2001 and now U.S. Pat. No. 6,566,368, which is a continuation-in-part of U.S. Ser. No. 09/606,919, filed on Jun. 29, 2000 and now U.S. Pat. No. 6,306,437, which is a continuation of U.S. Ser. No. 09/102,406, filed on Jun. 22, 1998 and now U.S. Pat. No. 6,121,276, which is a continuation-in-part of U.S. Ser. No. 08/546,498 filed on Oct. 20, 1995 and now U.S. Pat. No. 5,770,606, which in turn is a continuation-in-part of U.S. Ser. No. 08/231,250, filed on Apr. 22, 1994, abandoned.
Continuations (2)
|
Number |
Date |
Country |
Parent |
10044588 |
Oct 2001 |
US |
Child |
10440760 |
May 2003 |
US |
Parent |
09102406 |
Jun 1998 |
US |
Child |
09606919 |
Jun 2000 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09606919 |
Jun 2000 |
US |
Child |
10044588 |
Oct 2001 |
US |
Parent |
08546498 |
Oct 1995 |
US |
Child |
09102406 |
Jun 1998 |
US |
Parent |
08231250 |
Apr 1994 |
US |
Child |
08546498 |
Oct 1995 |
US |